ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 995,80
-0,77%
Dow Jones
38 852,86
-0,55%
DAX
18 570,27
-0,61%
Brent Oil
84,625
0,36%
Bitcoin
67 651,26
-0,94%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Avalon GloboCare Corporation (AVCO)

  7. Avalon GloboCare Corporation (AVCO) Actualités

AVCO

Avalon GloboCare (AVCO)

Avalon GloboCare Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AVCO
DateHeureSourceTitreSymboleSociété
29/06/202322h32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AVCOAvalon GloboCare Corporation
29/06/202312h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVCOAvalon GloboCare Corporation
26/05/202323h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVCOAvalon GloboCare Corporation
26/05/202313h01Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:AVCOAvalon GloboCare Corporation
22/05/202322h16Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AVCOAvalon GloboCare Corporation
16/05/202314h58Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:AVCOAvalon GloboCare Corporation
30/03/202322h37Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AVCOAvalon GloboCare Corporation
23/03/202311h04Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:AVCOAvalon GloboCare Corporation
09/03/202317h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVCOAvalon GloboCare Corporation
12/12/202216h41Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVCOAvalon GloboCare Corporation
21/11/202222h32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AVCOAvalon GloboCare Corporation
14/11/202222h51Edgar (US Regulatory)Proxy Statement - Other Information (preliminary) (pre 14c)NASDAQ:AVCOAvalon GloboCare Corporation
09/11/202222h00GlobeNewswire Inc.Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”NASDAQ:AVCOAvalon GloboCare Corporation
08/11/202215h10GlobeNewswire Inc.Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 MillionNASDAQ:AVCOAvalon GloboCare Corporation
29/09/202215h00GlobeNewswire Inc.Avalon GloboCare Receives Allowance for Joint U.S. PatentNASDAQ:AVCOAvalon GloboCare Corporation
08/08/202215h00GlobeNewswire Inc.Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical SocietyNASDAQ:AVCOAvalon GloboCare Corporation
28/07/202212h09BenzingaWhy Meta Platforms Is Trading Lower By More Than 6%: Here Are 34 Stocks Moving PremarketNASDAQ:AVCOAvalon GloboCare Corporation
25/05/202215h00GlobeNewswire Inc.Avalon GloboCare to Present at the Jefferies 2022 Healthcare ConferenceNASDAQ:AVCOAvalon GloboCare Corporation
18/05/202215h00GlobeNewswire Inc.Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular TherapyNASDAQ:AVCOAvalon GloboCare Corporation
27/04/202215h00GlobeNewswire Inc.Avalon GloboCare Expands IP Portfolio; Files 16 New Patent ApplicationsNASDAQ:AVCOAvalon GloboCare Corporation
14/02/202215h00GlobeNewswire Inc.Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell TherapiesNASDAQ:AVCOAvalon GloboCare Corporation
04/01/202215h00GlobeNewswire Inc.Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical ProgramsNASDAQ:AVCOAvalon GloboCare Corporation
22/12/202115h00GlobeNewswire Inc.Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to MarketNASDAQ:AVCOAvalon GloboCare Corporation
09/12/202115h00GlobeNewswire Inc.Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy DevelopmentNASDAQ:AVCOAvalon GloboCare Corporation
07/12/202115h04Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:AVCOAvalon GloboCare Corporation
14/10/202115h20GlobeNewswire Inc.Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular ImmunotherapyNASDAQ:AVCOAvalon GloboCare Corporation
07/10/202115h00GlobeNewswire Inc.Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related DiseasesNASDAQ:AVCOAvalon GloboCare Corporation
23/09/202115h00GlobeNewswire Inc.Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30thNASDAQ:AVCOAvalon GloboCare Corporation
13/09/202115h30GlobeNewswire Inc.Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of DirectorsNASDAQ:AVCOAvalon GloboCare Corporation
04/08/202115h00GlobeNewswire Inc.UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCareNASDAQ:AVCOAvalon GloboCare Corporation
 Showing the most relevant articles for your search:NASDAQ:AVCO

Dernières Valeurs Consultées

BIT
P1ZO47
NLBNPIT1ZO47 20241220 100
BIT
P1TKQ6
BNP Paribas Issuance
BIT
W237S8
UBS
LSE
FG12
Citi Fun 24
TSXV
CGN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés